Log in
Enquire now
‌

US Patent 10085982 Combinations

Patent 10085982 was granted and assigned to Astex Therapeutics Limited on October, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
‌
Astex Therapeutics Limited
Date Filed
March 26, 2015
Date of Patent
October 2, 2018
Patent Applicant
‌
Astex Therapeutics Limited
Patent Application Number
15128342
Patent Citations Received
‌
US Patent 11918576 Combination of an FGFR inhibitor and a CMET inhibitor
0
‌
US Patent 10736900 Combinations of an FGFR inhibitor and an IGF1R inhibitor
‌
US Patent 10898482 Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
‌
US Patent 11684620 Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
0
‌
US Patent 10272087 Pteridines as FGFR inhibitors
‌
US Patent 10421747 Quinoxaline derivatives useful as FGFR kinase modulators
‌
US Patent 10478494 FGFR/PD-1 combination therapy for the treatment of cancer
‌
US Patent 10519137 Pyrazolyl quinoxaline kinase inhibitors
‌
US Patent 11542247 Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
‌
US Patent 10716787 Combinations
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10085982
Patent Primary Examiner
‌
Venkataraman Balasubramanian

Find more entities like US Patent 10085982 Combinations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.